CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue, net	$ 30,654	$ 29,511
Cost of revenue	17,206	16,968
Gross profit	13,448	12,543
Operating expenses:
Selling and marketing	7,380	7,033
Research and development	2,128	1,366
General and administrative	8,558	4,219
Total operating expenses	18,066	12,618
Operating loss	(4,618)	(75)
Interest and other expense (income), net	2,199	(16)
Loss before income taxes and equity in losses of unconsolidated affiliates	(6,817)	(59)
Income tax (benefit) expense:
Current income tax expense	25	45
Deferred income tax benefit	(1,533)	(1,055)
Total income tax benefit	(1,508)	(1,010)
Net (loss) income before equity in losses of unconsolidated affiliates	(5,309)	951
Equity in losses of unconsolidated affiliates	(130)	(181)
Net (loss) income after equity in losses of unconsolidated affiliates	(5,439)	770
Net loss attributable to redeemable non-controlling interest	(151)	(44)
Net (loss) income attributable to Heska Corporation	$ (5,288)	$ 814
Earnings Per Share [Abstract]
Basic (loss) earnings per share attributable to Heska Corporation (in dollars per share)	$ (0.70)	$ 0.11
Diluted (loss) earnings per share attributable to Heska Corporation (in dollars per share)	$ (0.70)	$ 0.10
Weighted average outstanding shares used to compute basic (loss) earnings per share attributable to Heska Corporation (in shares)	7,568	7,459
Weighted average outstanding shares used to compute diluted (loss) earnings per share attributable to Heska Corporation (in shares)	7,568	7,965
Core companion animal
Revenue:
Total revenue, net	$ 27,306	$ 24,716
Other vaccines and pharmaceuticals
Revenue:
Total revenue, net	$ 3,348	$ 4,795